vs

Side-by-side financial comparison of REV Group, Inc. (REVG) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

REV Group, Inc. is the larger business by last-quarter revenue ($664.4M vs $622.0M, roughly 1.1× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 4.3%, a 30.1% gap on every dollar of revenue. On growth, REV Group, Inc. posted the faster year-over-year revenue change (11.1% vs 4.8%). Over the past eight quarters, REV Group, Inc.'s revenue compounded faster (6.5% CAGR vs 4.6%).

Rev is an American speech-to-text company that provides closed captioning, subtitles, and transcription services. The company, based in San Francisco and Austin, was founded in 2010. PC Magazine named the service an "Editor's Choice" in 2018, and ranked it as the best transcription service of 2019.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

REVG vs RPRX — Head-to-Head

Bigger by revenue
REVG
REVG
1.1× larger
REVG
$664.4M
$622.0M
RPRX
Growing faster (revenue YoY)
REVG
REVG
+6.3% gap
REVG
11.1%
4.8%
RPRX
Higher net margin
RPRX
RPRX
30.1% more per $
RPRX
34.4%
4.3%
REVG
Faster 2-yr revenue CAGR
REVG
REVG
Annualised
REVG
6.5%
4.6%
RPRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
REVG
REVG
RPRX
RPRX
Revenue
$664.4M
$622.0M
Net Profit
$28.9M
$214.2M
Gross Margin
15.4%
Operating Margin
7.1%
62.4%
Net Margin
4.3%
34.4%
Revenue YoY
11.1%
4.8%
Net Profit YoY
-30.7%
2.9%
EPS (diluted)
$0.57
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
REVG
REVG
RPRX
RPRX
Q4 25
$664.4M
$622.0M
Q3 25
$644.9M
$609.3M
Q2 25
$629.1M
$578.7M
Q1 25
$525.1M
$568.2M
Q4 24
$597.9M
$593.6M
Q3 24
$579.4M
$564.7M
Q2 24
$616.9M
$537.3M
Q1 24
$586.0M
$568.0M
Net Profit
REVG
REVG
RPRX
RPRX
Q4 25
$28.9M
$214.2M
Q3 25
$29.1M
$288.2M
Q2 25
$19.0M
$30.2M
Q1 25
$18.2M
$238.3M
Q4 24
$41.7M
$208.2M
Q3 24
$18.0M
$544.0M
Q2 24
$15.2M
$102.0M
Q1 24
$182.7M
$4.8M
Gross Margin
REVG
REVG
RPRX
RPRX
Q4 25
15.4%
Q3 25
15.8%
Q2 25
15.2%
Q1 25
13.3%
Q4 24
13.2%
Q3 24
13.5%
Q2 24
12.5%
Q1 24
10.7%
Operating Margin
REVG
REVG
RPRX
RPRX
Q4 25
7.1%
62.4%
Q3 25
8.8%
70.1%
Q2 25
7.9%
36.3%
Q1 25
5.3%
94.0%
Q4 24
5.8%
60.9%
Q3 24
4.9%
Q2 24
3.7%
50.2%
Q1 24
-1.1%
-13.0%
Net Margin
REVG
REVG
RPRX
RPRX
Q4 25
4.3%
34.4%
Q3 25
4.5%
47.3%
Q2 25
3.0%
5.2%
Q1 25
3.5%
41.9%
Q4 24
7.0%
35.1%
Q3 24
3.1%
96.3%
Q2 24
2.5%
19.0%
Q1 24
31.2%
0.8%
EPS (diluted)
REVG
REVG
RPRX
RPRX
Q4 25
$0.57
$0.49
Q3 25
$0.59
$0.67
Q2 25
$0.38
$0.07
Q1 25
$0.35
$0.55
Q4 24
$1.03
$0.46
Q3 24
$0.35
$1.21
Q2 24
$0.28
$0.23
Q1 24
$3.06
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
REVG
REVG
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$34.7M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$416.3M
$9.7B
Total Assets
$1.2B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
REVG
REVG
RPRX
RPRX
Q4 25
$34.7M
$618.7M
Q3 25
$36.0M
$938.9M
Q2 25
$28.8M
$631.9M
Q1 25
$31.6M
$1.1B
Q4 24
$24.6M
$929.0M
Q3 24
$50.5M
$950.1M
Q2 24
$38.2M
$1.8B
Q1 24
$87.9M
$843.0M
Total Debt
REVG
REVG
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
REVG
REVG
RPRX
RPRX
Q4 25
$416.3M
$9.7B
Q3 25
$387.3M
$9.6B
Q2 25
$357.8M
$9.5B
Q1 25
$428.8M
$9.8B
Q4 24
$435.1M
$10.3B
Q3 24
$394.6M
$10.3B
Q2 24
$379.7M
$9.8B
Q1 24
$496.1M
$9.9B
Total Assets
REVG
REVG
RPRX
RPRX
Q4 25
$1.2B
$19.6B
Q3 25
$1.2B
$19.3B
Q2 25
$1.2B
$18.3B
Q1 25
$1.2B
$17.6B
Q4 24
$1.2B
$18.2B
Q3 24
$1.3B
$18.0B
Q2 24
$1.3B
$17.7B
Q1 24
$1.4B
$16.1B
Debt / Equity
REVG
REVG
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
REVG
REVG
RPRX
RPRX
Operating Cash FlowLast quarter
$76.9M
$827.1M
Free Cash FlowOCF − Capex
$53.7M
FCF MarginFCF / Revenue
8.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
2.66×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$190.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
REVG
REVG
RPRX
RPRX
Q4 25
$76.9M
$827.1M
Q3 25
$60.3M
$702.6M
Q2 25
$117.0M
$364.0M
Q1 25
$-13.1M
$596.1M
Q4 24
$68.6M
$742.5M
Q3 24
$14.4M
$703.6M
Q2 24
$40.1M
$658.2M
Q1 24
$-69.7M
$664.6M
Free Cash Flow
REVG
REVG
RPRX
RPRX
Q4 25
$53.7M
Q3 25
$48.7M
Q2 25
$105.6M
Q1 25
$-18.0M
Q4 24
$63.3M
Q3 24
$8.5M
Q2 24
$34.2M
Q1 24
$-80.2M
FCF Margin
REVG
REVG
RPRX
RPRX
Q4 25
8.1%
Q3 25
7.6%
Q2 25
16.8%
Q1 25
-3.4%
Q4 24
10.6%
Q3 24
1.5%
Q2 24
5.5%
Q1 24
-13.7%
Capex Intensity
REVG
REVG
RPRX
RPRX
Q4 25
3.5%
Q3 25
1.8%
Q2 25
1.8%
Q1 25
0.9%
Q4 24
0.9%
Q3 24
1.0%
Q2 24
1.0%
Q1 24
1.8%
Cash Conversion
REVG
REVG
RPRX
RPRX
Q4 25
2.66×
3.86×
Q3 25
2.07×
2.44×
Q2 25
6.16×
12.06×
Q1 25
-0.72×
2.50×
Q4 24
1.65×
3.57×
Q3 24
0.80×
1.29×
Q2 24
2.64×
6.45×
Q1 24
-0.38×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

REVG
REVG

Specialty Vehicles$507.4M76%
Recreational Vehicles$157.2M24%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons